
Britain’s bond crisis reverses over the government
New finance minister Jeremy Hunt has scrapped most of his predecessor’s unfunded tax cuts, scuppering Prime Minister Liz Truss’s growth plan. In this Viewsroom podcast, Breakingviews columnists debate...
20 Okt 202215min

Elon Musk’s second run at his $44 bln Twitter deal
A judge in Delaware has given the Tesla CEO until the end of the month to make good on his vow to buy the social media giant. In this Viewsroom podcast, Breakingviews columnists delve into the many tw...
13 Okt 202214min

What to expect from China’s Party Congress
This month’s quinquennial meeting will shed some light on President Xi Jinping’s policy priorities amid a slowing economy and Covid lockdowns. In this Viewsroom podcast, Breakingviews columnists offer...
6 Okt 202222min

Behind Britain’s self-inflicted financial crisis
Sterling fell to a record low and gilt yields soared after finance minister Kwasi Kwarteng unveiled a raft of unfunded tax cuts. In this Viewsroom podcast, Breakingviews columnists explain the long-te...
28 Sep 202219min

Italy’s first female leader, Amazon’s monopoly
Far-right leader Giorgia Meloni is favourite to become prime minister after Sunday’s election. In this Viewsroom podcast, Breakingviews columnists debate how she will handle Rome’s debt, which is expe...
22 Sep 202222min

Disney’s big ESPN choice, Rio Tinto Mongolia drama
Activist Dan Loeb backed away from his demand that the $203 bln media firm sell its sports network. In this Viewsroom podcast, Breakingviews columnists debate whether it’s the right move. And the $94 ...
15 Sep 202218min

The consequences of Europe’s energy crisis
As Russian President Vladimir Putin cuts off gas through a key pipeline, Breakingviews columnists discuss the response from UK and European governments, how the shutdown could have some longer-term be...
8 Sep 202219min

Chinese audits, Vaccine wars, UK tax cuts
Beijing will let companies submit to U.S. audit requirements. In this Viewsroom podcast, Breakingviews columnists argue only weak firms will comply. Also, Pfizer and Moderna’s legal battle is unlikely...
1 Sep 202226min




















